| Sub Cat | Target Species | Isotype | Application | Affinity | |
|---|---|---|---|---|---|
| V3S-1124-YC650 | Human, Cynomolgus | IgG4 | ELISA; Block; FuncS | 42 pM-740 pM for human, 554 pM for monkey | |
| V3S-0522-YC6484 | Human | IgG | ELISA; FC; Block; WB | ||
| V3S-0622-YC181 | Human | IgG1 | ELISA; Block; FuncS | 26 pM | |
| V3S-0522-YC1022 | Human | IgG1 | ELISA | ||
| V3S-1022-YC1445 | Human | IgG1 | WB; ELISA | 69 pM | |
| V3S-1022-YC1446 | Human | IgG1 | WB; ELISA | 121 pM | |
| V3S-1022-YC1447 | Human | IgG1 | WB; ELISA | 70 pM |
| Description | This product is a human monoclonal antibody that reacts with FLT1. Antibody II showed good selectivity for VEGFR1 by not binding to VEGFR2 and VEGFR3 up to 200 nM of receptor. Antibody II has tight picomolar affinity for human VEGFR1 (~740 pM) and cynomolgus VEGFR1 (~554 pM). Antibody II neutralizes human VEGF-A and P1GF binding to VEGFR1 with an IC50 of 1.02 nM and 0.31 nM, respectively. It also suppresses human VEGF-A and P1GF stimulated VEGFR1 phosphorylation. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human, Cynomolgus |
| Affinity | 42 pM-740 pM for human, 554 pM for monkey |
| Isotype | IgG4 |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | ELISA; Block; FuncS |
| Application Notes | Neutralization assay For the solid phase ELISA, a 96-well plate may be coated with 1 μg/mL of hVEGFR1-Fc in PBS at 50 μl/well, and then incubated overnight at 4°C. Then the wells may be blocked for an hour with 100 μl of 1% casein at room temperature. Antibodies were titrated in a microtiter plate against PBST starting at 50 μg/mL, and diluting with 1:3 dilutions to 0.023 μg/mL. The ELISA plate may be washed 3 times and then 50 μl/well of pre-titrated antibody may be added. After an hour incubation at 37°C, 50 μl of biotinylated ligand (2 nM hPLGF1 or 2 nM hVEGFA-165) was added to each well, and incubation continued at 37°C for 30 min. The plate was washed and then 50 μl/well of NA-AP (1:1000 dilution) was added, with an incubation at room temperature of 15 min. After washing three more times, 100 μl/well of PMP (1:35 diluted in water) were added. The plate may then be developed for 30 min and read at OD560. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | FLT1 |
| Alternative Name | FLT; FLT-1; VEGFR1; VEGFR-1; vascular endothelial growth factor receptor 1; fms-like tyrosine kinase 1; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor); tyrosine-protein kinase FRT; tyrosine-protein kinase receptor FLT; vascular permeability factor receptor |
| Gene ID | 2321 |
| UniProt | P17948 |
| Research Area | Cardiovascular; Signal Pathway |
